Report: Aggressive Qiagen Grows and Increases Product Offering in 2015
NEW YORK, Nov. 24, 2015 /PRNewswire/ -- Qiagen has continued to be an aggressive, growing player in the in vitro diagnostic (IVD) market in 2015, according to Kalorama Information. The healthcare market researcher said that the company has expanded its test menu through key acquisitions and ventured further into market segments such as next-generation sequencing. Kalorama Information profiled the company in a recent report as part of a series on major IVD companies. The healthcare market researcher's report, QIAGEN: Company Profile, examines the Netherlands-based healthcare company.
QIAGEN: Company Profile can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=88091&productid=9402629.
Qiagen markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Qiagen is a leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue.
The report said that Qiagen has continued to expand their test menu through various acquisitions. For example, Qiagen acquired AdnaGen's technology for the enrichment and molecular analysis of circulating tumor cells in March 2015. AdnaGen's AdnaTests have been developed and marketed for recommended use with Qiagen's platforms and reagent kits. Included in the transaction were the CE-marked products AdnaTest BreastCancer and AdnaTest Prostate Cancer. The AdnaGen name was changed to Qiagen Hannover.
In January 2015, Qiagen acquired the Enzyme Solutions Unit of Enzymatics, a leader in the development, manufacturing, and supply of enzymes essential to driving the adoption of next-generation sequencing (NGS) and other genetic analysis technologies in life sciences research and clinical healthcare.
These past several years of aggressive technology acquisition and internal development culminated for Qiagen with the launch of its comprehensive NGS workflow, the GeneReader system, in November. The GeneReader NGS system, which is geared toward clinical laboratories, is not a standalone sequencing platform but an integrated package with multiple components that cover all steps to analyze a tissue sample, including sample and library preparation, target enrichment, sequencing, data analysis, and clinical reporting. The research and clinical NGS solution will expand Qiagen's market opportunity in NGS markets with product sales from sample preparation through automated interpretation of clinical sequencing results.
Qiagen will face challenges in gaining market share in the NGS library prep and target enrichment segment. Strong competitors include Illumina, Agilent, Thermo Fisher, and Fluidigm. However, Qiagen's position in NGS markets is set to rise substantially, particularly as it more thoroughly addresses the market for sequencing assays in clinical oncology – a market space expected by Kalorama Information to grow at a substantially higher annual rate than the overall cancer diagnostics market through 2019.
The information presented in QIAGEN: Company Profile is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.
QIAGEN: Company Profile can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=88091&productid=9402629.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article